Skip to content

Tirzepatide: Side Effects & Safety

Part of the Tirzepatide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Common Side Effects

  • Nausea (12–24%): Most common during titration, improves with continued use
  • Diarrhea (12–17%): Mild to moderate, most common during dose increases
  • Decreased appetite (5–11%)
  • Vomiting (5–9%)
  • Constipation (5–7%)
  • Abdominal pain (5–7%)
  • Injection site reactions (3–5%)

GI side effects are most common during the dose-escalation phase and typically diminish with continued treatment at a stable dose.

Serious Risks

  • Pancreatitis: Cases reported in trials. Discontinue if suspected.
  • Thyroid C-cell tumors: Boxed warning. GLP-1 agonists caused thyroid tumors in rodents. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
  • Gallbladder events: Increased cholelithiasis (gallstones) likely related to rapid weight loss.
  • Hypoglycemia: Low risk alone; increased with insulin or sulfonylureas.

For the complete overview, see the tirzepatide complete guide.

References

  1. Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity. NEJM, 2022.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.